Acticor Biotech: falls after capital increase

(CercleFinance.com) - Acticor Biotech is down 22% after announcing the completion of a capital increase for a total gross amount of eight million euros, through the issue of 2,566,086 new shares at a price of 3.
13 euros per share.

The biopharmaceutical company will use the proceeds of this capital increase to pursue its development plan in the emergency treatment of stroke, including the completion of the phase 2/3 ACTISAVE study.

On the basis of planned expenditure, net cash and financial debt at December 31, 2023, and the funds raised, Acticor estimates that it will be in a position to finance its operations until October 2024.

Copyright (c) 2024 CercleFinance.com. All rights reserved.